

17th April 2018

The Manager- Listing

BSE Limited

Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai - 400001

The Manager- Listing

National Stock Exchange of India Limited

Exchange plaza, 5th Floor, Plot No. C/1, G Block
Bandra –Kurla Complex, Bandra (E),
Mumbai - 400051

Dear Sir(s),

Sub: News Release dated 17th April 2018

Please find enclosed a copy of the News Release being issued titled:

“AstraZeneca strengthens innovation partnership in India”.

Please take the same on record.

Thanking you,

For **AstraZeneca Pharma India Limited**



Pratap Rudra

Company Secretary & Legal Counsel

Encl: As above.

AstraZeneca strengthens innovation partnership in India

Following the signature of the bilateral innovation partnership for a sustainable future between Sweden and India, AstraZeneca announces an investment of USD 90 million in India over the next 5 years to develop local skills, build scientific innovation and promote quality manufacturing with the aim to improve overall health outcomes in the country

17th April 2018: Leading global science-led biopharmaceutical company AstraZeneca today announced its decision of further investing \$ 90 million over the next 5 years in India. The announcement was made following a meeting between the company's Executive Vice President for International Region – Mr. Leon Wang and Honorable Prime Minister of India, Shri Narendra Modi, during the latter's visit to Sweden, where the two countries signed a joint declaration on innovation partnership for a sustainable future.

This investment commitment will span across AstraZeneca's diverse footprint in India with an aim to strengthen its manufacturing, clinical operations, patient safety & regulatory science, IT services and commercial operations. Furthermore this investment will support scientific data generation, quality manufacturing, science talent development and collaborative development of innovative solutions to improve the standard of care of non-communicable diseases in India. The commitment also aligns closely with the Indian government's initiatives to create a stronger business, innovation, and healthcare environment such as "Skill India", "National Health Policy" and "Ayushman Bharat."

Leon Wang, Executive Vice President for International Region, AstraZeneca, said *"AstraZeneca has a long-standing commitment in India of 40 years. Our latest investment reflects our commitment to address the unmet needs in non-communicable diseases, enable high-value job creation and boost medical innovation in the country. We believe, this investment commitment across AstraZeneca's business footprint in India, will make a positive impact. It also aligns closely with the government's vision for healthcare and innovation."*

AstraZeneca's strategy in India is to address the growing burden of non-communicable diseases. The company invests in many initiatives and programs such as the Young Health Programme, Early action in Diabetes & Healthy Lung for early action in awareness, prevention, detection and holistic management of non-communicable diseases.

At present, AstraZeneca has a workforce of over 4000 employees in India spanning manufacturing, sales and marketing, clinical operations, IT services, digital services and

Global medicines development. The company recently announced expansion of its Global Technology Centre (GTC) in Chennai, now employing more than 2000 employees. GTC is AstraZeneca's first, insourced IT facility. AstraZeneca's manufacturing facility in Bengaluru has a sophisticated production facility designed to meet the most stringent international standards, conforming to World Health Organisation cGMP (current Good Manufacturing Practices) norms. AstraZeneca also has a sizeable clinical operation and is expanding its Global medicines development unit that focusses on patient safety and regulatory science in India.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

About AstraZeneca India

AstraZeneca has a long history and a strong footprint in India. This year, AstraZeneca will celebrate its 40th business anniversary in India. AstraZeneca is present in India through 2 legal entities:

- AstraZeneca Pharma India Limited (AZPIL), a listed company, established in 1979 and headquartered in Bengaluru, Karnataka has a workforce of over 1200 employees and is the operating company covering manufacturing, sales and marketing activities. It is listed on the Indian Stock Exchanges. It has an innovative portfolio to address the unmet needs in non-communicable diseases such as diabetes, heart disease, cancer, asthma & COPD.
- AstraZeneca India Private Limited (AZIPL), is a private entity, established in 1986, covering AZ's Global Technology Centre (GTC) in Chennai with a workforce of more than 2000 employees. It also includes AstraZeneca's science unit - Global Medicines Development Group (GMD), the clinical operations unit and the digital unit i.e. Global Commercial Operation within Global Business Services.

Contact:

Kathleen Goh
Communications Director Asia Area
+ 6581815128/ Kathleen.goh@astrazeneca.com

Varsha Das
Corporate Affairs – AstraZeneca Pharma India
Limited
+91.9008777884/
Varsha.das1@astrazeneca.com

Parvathy Ashok
Corporate Communications – AstraZeneca India
Private Limited
Parvathy.ashok@astrazeneca.com

Nupur Bharadwaj
Edelman India
+91
9818166416/Nupur.Bhardwaj@edelman.com